Demographic, Clinical, Laboratory and Genetical Characteristics of Patients With Beta Thalassemia Intermedia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01443312|
Recruitment Status : Completed
First Posted : September 29, 2011
Last Update Posted : November 1, 2019
|Condition or disease||Intervention/treatment|
|Thalassemia||Genetic: Laboratory analysis.|
The characteristics that will be recorded from the medical files include: demographic data, included gender and ethnic origin, family history, age at diagnosis, number and frequency of blood transfusions including age of first transfusion and physical examination findings.
The laboratory data included iron metabolism parameters, mutation in the alfa and beta gene and the presence of the xmn1 polymorphism.
|Study Type :||Observational|
|Actual Enrollment :||28 participants|
|Official Title:||Demographic, Clinical, Laboratory and Genetical Characteristics of Patients With Beta Thalassemia Intermedia|
|Study Start Date :||October 2011|
|Actual Primary Completion Date :||December 2014|
|Actual Study Completion Date :||December 2014|
Thalassemia Intermedia Patients
Patients with Beta Thalassemia Intermedia treated at the Pediatric Hematology Unit. The characterization of Thalassemia Intermedia was based on age at diagnosis (Older than 2 ys) and / or clinical characteristics that are milder than Thalassemia Major in patients homozygous for beta globin genes.
Genetic: Laboratory analysis.
The blood transfusions given to the patients are in accord to physician decision and not related to the study
- The characteristics of patients with thalassemia intermedia [ Time Frame: One year ]Observational study that analyzed the characteristics of thalassemia intermedia patients
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01443312
|Pediatric Hematology Unit - Ha'Emek Medical Center|
|Afula, Israel, 18101|
|Principal Investigator:||Ariel Koren, MD||Ha'Emek Medical Center, Afula, Israel|